Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Citi
US Army
Julphar
Federal Trade Commission
Medtronic
Deloitte
Cerilliant
Boehringer Ingelheim
Accenture

Generated: February 21, 2018

DrugPatentWatch Database Preview

CARDENE Drug Profile

« Back to Dashboard

When do Cardene patents expire, and when can generic versions of Cardene launch?

Cardene is a drug marketed by Chiesi Usa Inc and is included in three NDAs. There are four patents protecting this drug and five Paragraph IV challenges.

The generic ingredient in CARDENE is nicardipine hydrochloride. There are eleven drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the nicardipine hydrochloride profile page.

US Patents and Regulatory Information for CARDENE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chiesi Usa Inc CARDENE nicardipine hydrochloride CAPSULE;ORAL 019488-001 Dec 21, 1988 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Chiesi Usa Inc CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-005 Nov 7, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Chiesi Usa Inc CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-004 Nov 7, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Chiesi Usa Inc CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-004 Nov 7, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Chiesi Usa Inc CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-002 Jul 31, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Chiesi Usa Inc CARDENE SR nicardipine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020005-001 Feb 21, 1992 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Chiesi Usa Inc CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-003 Jul 31, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Chiesi Usa Inc CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-005 Nov 7, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Chiesi Usa Inc CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-005 Nov 7, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Chiesi Usa Inc CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-002 Jul 31, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for CARDENE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Chiesi Usa Inc CARDENE nicardipine hydrochloride CAPSULE;ORAL 019488-001 Dec 21, 1988 ➤ Sign Up ➤ Sign Up
Chiesi Usa Inc CARDENE nicardipine hydrochloride INJECTABLE;INJECTION 019734-001 Jan 30, 1992 ➤ Sign Up ➤ Sign Up
Chiesi Usa Inc CARDENE nicardipine hydrochloride INJECTABLE;INJECTION 019734-001 Jan 30, 1992 ➤ Sign Up ➤ Sign Up
Chiesi Usa Inc CARDENE nicardipine hydrochloride INJECTABLE;INJECTION 019734-001 Jan 30, 1992 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for CARDENE
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Injection 0.1 mg/mL, 200 mL and0.2mg/mL, 200 mL ➤ Subscribe 6/20/2013
➤ Subscribe Injection 0.1 mg/mL, 200 mL and0.2mg/mL, 200 mL ➤ Subscribe 6/20/2013
➤ Subscribe Injection 0.1 mg/mL, 200 mL and0.2mg/mL, 200 mL ➤ Subscribe 6/20/2013
➤ Subscribe Injection 0.1 mg/mL, 200 mL and0.2mg/mL, 200 mL ➤ Subscribe 6/20/2013
➤ Subscribe Injection 2.5 mg/mL, 10 mL Ampoules ➤ Subscribe 12/27/2006

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Cantor Fitzgerald
US Department of Justice
Fish and Richardson
Harvard Business School
McKesson
Argus Health
Covington
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot